Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,624 across all filing types
Latest filing 2025-05-12 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-05-12 English
VOLUNTARY ANNOUNCEMENT - NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED MARKETING APPROVAL FOR DISITAMAB VEDOTIN FOR INJECTION FOR THE TREATMENT OF HER2-POSITIVE ADVANCED BREAST CANCER WITH LIVER ME
Regulatory Filings Classification · 85% confidence The document is a voluntary announcement on the Hong Kong Exchange regarding regulatory approval of a new drug indication by the National Medical Products Administration. It is not an earnings release, management discussion, or formal financial report but a company announcement of a product approval. This falls under the general regulatory announcements category (RNS) as it does not match a more specific filing type.
2025-05-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2025
Regulatory Filings Classification · 95% confidence The document is an Exchange Listing Rules Form FF301 – Monthly Return for Equity Issuer and Hong Kong Depositary Receipts under Chapter 19B submitted to HKEX. It details movements in authorised share capital, issued shares, treasury shares, and related confirmations. It does not constitute an earnings release, annual/interim report, or management presentation, but is a routine regulatory submission under listing rules. Therefore, it falls under the general “Regulatory Filings” category.
2025-05-07 English
Monthly Return of Equity Issuer on Movement in Securities for the month ended 30 April 2025
Regulatory Filings Classification · 91% confidence The document is a monthly regulatory return (Form FF301) filed with the Hong Kong Stock Exchange, detailing movements in authorised share capital and issued shares under Chapter 19B of the Listing Rules. It is neither an annual or interim financial report nor an earnings release, nor does it announce a specific corporate action (e.g., share issue, repurchase, dividend). It is a standard periodic submission to the regulator. No specialized category (e.g., POS for buybacks or SHA for capital changes) applies since no transactions occurred. Accordingly, it fits the fallback category for miscellaneous regulatory filings.
2025-05-06 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-04-30 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-04-28 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.